Turning glycan engineering into new therapies
Kyron Bio makes N-glycans programmable, opening new possibilities for therapeutic design. We're applying our platform to a growing pipeline of drug candidates.
Our pipeline of glycan-engineered therapeutics
1. Silencing immunogenicity
KB-1001
validated ex vivo in two disease areas
TNFα
In vivo
2. Glycan conjugation
KB-2001
Single payload
ADC
Undisclosed
PoC
KB-2002
Dual payload
ADC
Undisclosed
PoC
KB-3001
Dual payload
RLT
Undisclosed
PoC
Pipeline developed alongside active collaborations with pharma partners.
Partner with Kyron Bio to make better therapies for patients.
Paris Biotech Santé - Site Cochin
27 rue du Faubourg Saint Jacques
75014 Paris, France